Literature DB >> 11112219

Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations.

B A Werness1, S J Ramus, A S Whittemore, K Garlinghouse-Jones, I Oakley-Girvan, R A Dicioccio, Y Tsukada, B A Ponder, M S Piver.   

Abstract

Breast cancers from patients with germline BRCA1 mutations show characteristic histopathologic features. However, similar studies of BRCA1-associated ovarian cancers have reported inconsistent findings. Interobserver differences in histopathologic classification are a significant source of variation, and most studies have obtained histopathologic information from pathology reports rather than from review of histopathology slides. We therefore reviewed the histopathology slides and pathology reports to determine histologic type, grade, and stage for cancers of the ovary or peritoneum in 217 women from 126 families enrolled in the Gilda Radner Familial Ovarian Cancer Registry. Peripheral blood DNA from at least 1 affected member of each family was analyzed for BRCA1 mutations, and tumors from BRCA1 mutation-positive families were compared with those from BRCA1-negative families. Of 66 patients from 36 BRCA1-positive families, 64 had ovarian carcinoma, 1 had an ovarian carcinoma in situ, and 1 had a dysgerminoma. Of 151 patients from 90 BRCA1-negative families, 135 had ovarian carcinoma, 10 had ovarian borderline tumors, 3 had ovarian sex cord/stromal tumors, and 3 had primary peritoneal carcinoma. There were fewer grade 1 (P <.001) and stage I (P =.10) cancers in patients from BRCA1-positive families than in patients from BRCA1-negative families. Neither mucinous nor borderline tumors were found in the BRCA1-positive families. Ovarian cancers arising in women from BRCA1-positive families are more likely to be high grade and nonmucinous than cancers arising in women from BRCA1-negative families. The absence of borderline tumors in patients from BRCA1-positive families adds to accumulating evidence that BRCA1 mutations do not play a role in the development of these tumors. HUM PATHOL 31:1420-1424. Copyright 2000 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112219

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.

Authors:  D G R Evans; D M Eccles; N Rahman; K Young; M Bulman; E Amir; A Shenton; A Howell; F Lalloo
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

2.  Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.

Authors:  James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate
Journal:  Gynecol Oncol       Date:  2013-12-12       Impact factor: 5.482

3.  Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.

Authors:  Mika Fujiwara; Valerie A McGuire; Anna Felberg; Weiva Sieh; Alice S Whittemore; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2012-08       Impact factor: 6.394

Review 4.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

5.  Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.

Authors:  Jurgen M J Piek; Bas Torrenga; Brenda Hermsen; René H M Verheijen; Ronald P Zweemer; Johan J P Gille; Peter Kenemans; Paul J van Diest; Fred H Menko
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

Review 6.  Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Dawn C Allain
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

7.  Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.

Authors:  Karen M Chisholm; Barbara A Goff; Rochelle Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Cancer Genet Cytogenet       Date:  2008-05

Review 8.  BRCA-associated ovarian cancer: from molecular genetics to risk management.

Authors:  Giulia Girolimetti; Anna Myriam Perrone; Donatella Santini; Elena Barbieri; Flora Guerra; Simona Ferrari; Claudio Zamagni; Pierandrea De Iaco; Giuseppe Gasparre; Daniela Turchetti
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

9.  Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.

Authors:  Nicoletta Biglia; Paola Sgandurra; Valentina Elisabetta Bounous; Furio Maggiorotto; Eleonora Piva; Emanuele Pivetta; Riccardo Ponzone; Barbara Pasini
Journal:  Ecancermedicalscience       Date:  2016-05-03

10.  Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?

Authors:  Brent D Kerger; Robert C James; David A Galbraith
Journal:  Front Genet       Date:  2014-05-30       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.